Every material Form 8-K Nexalin Technology, Inc. has filed with the SEC since September 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Nexalin Technology received Nasdaq confirmation on September 30, 2026 that it has regained compliance with the $1.00 minimum bid price requirement. The company still must show at least $2,500,000 in stockholders' equity by January 4, 2027, or its stock faces delisting from Nasdaq.
Nasdaq confirmed on September 30, 2026 that the bid price requirement of $1.00 per share is met
Remaining condition: stockholders' equity of at least $2,500,000 by January 4, 2027
The company says it intends to meet the equity requirement, but gives no assurance it will
Nexalin Technology entered a 10-year exclusive distribution agreement, effective September 22, 2026, with Inovanexa Medical Technologies S.A. for its Nexalin Sync device in seven countries. The filing discloses no purchase value or revenue figures, and the company says it is pre-revenue, so the financial effect for shareholders depends on purchase orders and the performance requirements that the distributor must meet.
Exclusivity covers Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela, with a 10-year initial term that renews automatically if performance requirements are met.
The 8-K says the distributor must place an initial binding order for five devices at signing, with a clinical pilot targeted within 90 days. The press release says the binding order is for 10 devices, with five delivered immediately.
After the first 30 devices are purchased, the distributor must set up a local manufacturing facility in Brazil at its own cost, and Nexalin would receive per-device compensation and disposable royalties.
The filing states the distributor is not otherwise obligated to buy more devices, and the company's risk disclosures say it may never recognize revenue beyond the initial order.
Nexalin Technology received a Nasdaq Hearings Panel decision allowing its common stock to stay listed on The Nasdaq Capital Market, subject to conditions. The company must meet the $1.00 minimum bid price by September 28, 2026 and the $2,500,000 stockholders' equity requirement by January 4, 2027, or its stock faces delisting.
Panel granted continued listing in a notice received September 25, 2026.
Company must show a closing bid price of $1.00 or greater for at least 20 consecutive trading sessions.
Stockholders' equity must meet the $2,500,000 minimum by January 4, 2027.
Filing states there can be no assurance the company will meet the conditions.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Nexalin Technology, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →